Print    Email
Decrease (-) Restore Default Increase (+)

News Releases

Media Contact: Heidi Press, Public Relations Specialist St. Joseph Mercy Oakland 44405 Woodward Avenue Pontiac, MI 48341 248-858-6662

SJMO Hosts Free Fibromyalgia Forum
Start Date

St. Joseph Mercy Oakland To Host Free Public Forum
Focusing On Fibromyalgia

Cerephex Corp. Joins Hospital for Presentation for Fibromyalgia Patients and Their Families

Pontiac, Mich.—St. Joseph Mercy Oakland (SJMO) and Cerephex Corp. will host a free public form for fibromyalgia patients and their family members at 7 p.m., Tuesday,  Feb. 12, 2013 at the Oakland Ballroom at the Auburn Hills Marriott Pontiac at Centerpoint, 2600 Centerpoint Parkway, Pontiac, 48341.

Globally recognized experts on fibromyalgia will discuss current medical science and thinking about this painful and difficult-to-treat condition.  They also will discuss new horizons in fibromyalgia treatment, including research on new device-based therapies being studied at SJMO

Fibromyalgia is a condition characterized by chronic widespread pain in all parts of the body.  Fatigue, sleep problems and multiple tender points on the body also are very common.  While no one knows the exact cause of fibromyalgia, there is evidence that people with the condition may be more sensitive to pain because something is wrong with the brain’s usual pain perception processes. 

Although fibromyalgia can be debilitating for some people, it is not degenerative or life threatening, and one can manage symptoms and improve quality of life with professional and self-care.  Medical researchers have shown that fibromyalgia can be treated, and FDA-approved treatments now exist for this condition.

Speakers at the community forum include:

  • Daniel Clauw, MD, a world-leading expert on the fundamental causes and treatment strategies for fibromyalgia, fatigue and other chronic pain conditions
  • R. Michael Gendreau, MD, PhD, whose expertise focuses on development of new approaches to the treatment of fibromyalgia and other functional somatic syndromes
  • Jeffrey Hargrove, PhD, whose expertise includes development of technologies for assessing centralized pain and for treating fibromyalgia using noninvasive neurostimulation.

A clinical study evaluating a new and experimental medical device treatment for fibromyalgia is being conducted at SJMO.  The medical device is called NeuroPoint®, and the purpose for the study is to help medical researchers learn whether or not NeuroPoint is effective in reducing fibromyalgia symptoms and improving quality of life for patients enrolled in the study.

The device sends a gentle signal delivered through a sensor that simply rests near the scalp.  A second sensor rests on the right ear.  The treatment provided by the device is called Reduced Impedance Noninvasive Cortical Electrostimulation.  The NeuroPoint delivers therapeutic electrical stimulation to regions of the brain that are believed to be involved in the abnormal pain processing of fibromyalgia.  The therapy involves a total of 24 treatment sessions over 12 weeks and a final follow-up evaluation.  Each session lasts about 20 minutes plus an additional 30-60 minutes for patient evaluation and testing at each visit. This research study does not involve the use of medications or drugs. 

Everyone with fibromyalgia or who has a loved one with fibromyalgia is welcome.

Free parking is available. For questions, call 248-254-6480 or toll-free 800-787-5940.

A Member of Trinity Health
© 2015 Trinity Health

St. Joseph Mercy Oakland | 44405 Woodward Avenue, Pontiac, Michigan 48341 | 248-858-3000